公开(公告)号：EP0889969B1

公开(公告)日：2005-11-09

申请号：EP97914375.7

申请日：1997-03-12

申请人： Aventis Pharma S.A. ,  LUDWIG INSTITUTE FOR CANCER RESEARCH

发明人： BOON, Falleur ,  DUFFOUR, Marie-Thérèse ,  HADDADA, Hedi ,  LURQUIN, Christophe ,  PERRICAUDET, Michel ,  UYTTENHOVEGHESQUIERE, Catherine ,  WARNIER, Guy

IPC分类号： C12N15/86 ,  C07K14/705 ,  A61K48/00 ,  C12N5/10 ,  A61K39/00 ,  C12N15/12

CPC分类号： C07K14/4748 ,  A61K48/00 ,  A61K2039/51 ,  C12N2799/022

公开(公告)号：EP0889969A1

公开(公告)日：1999-01-13

申请号：EP97914375.0

申请日：1997-03-12

申请人： RHONE-POULENC RORER S.A. ,  LUDWIG INSTITUTE FOR CANCER RESEARCH

发明人： BOON, Falleur ,  DUFFOUR, Marie-Thérèse ,  HADDADA, Hedi ,  LURQUIN, Christophe ,  PERRICAUDET, Michel ,  UYTTENHOVEGHESQUIERE, Catherine ,  WARNIER, Guy

IPC分类号： C12N15 ,  A61K31 ,  A61K35 ,  A61K39 ,  A61K48 ,  A61P35 ,  C07K14 ,  C12N7

CPC分类号： C07K14/4748 ,  A61K48/00 ,  A61K2039/51 ,  C12N2799/022

摘要： A method for treating human tumours by gene therapy is disclosed. In particular, defective recombinant viruses with a sequence coding for a human tumour-specific antigen, and the use thereof for treating or preventing human tumours, as well as producing specific cytotoxic T-cells (CTLs) in vitro or ex vivo, are disclosed. Pharmaceutical compositions comprising said viruses, particularly in injectable form, are also disclosed.

公开(公告)号：EP0695360B1

公开(公告)日：2006-07-05

申请号：EP94913649.3

申请日：1994-04-15

申请人： Aventis Pharma S.A.

发明人： PERRICAUDET, Michel ,  HADDADA, Hedi ,  MAY, Evelyne

IPC分类号： C12N15/86 ,  A61K48/00 ,  C12N15/12 ,  C12N15/11

CPC分类号： C07K14/82 ,  A61K35/761 ,  A61K38/1758 ,  A61K48/00 ,  C12N15/86 ,  C12N2710/10043 ,  C12N2710/10243 ,  C12N2710/10332 ,  C12N2710/10343 ,  A61K2300/00

摘要： Recombinant adenoviruses comprising a heterologous DNA sequence, preparation thereof, and use thereof for the treatment and/or prevention of cancer.

公开(公告)号：EP0752003B1

公开(公告)日：2006-03-15

申请号：EP95914389.2

申请日：1995-03-21

申请人： Aventis Pharma S.A.

发明人： BEMELMANS, Alexis ,  GEOFFROY, Marie-Claude ,  HORELLOU, Philippe ,  JULIEN, Jean-François ,  MALLET, Jacques ,  PERRICAUDET, Michel ,  ROBERT, Jean-Jacques ,  VIGNE, Emmanuelle

IPC分类号： C12N15/86 ,  A61K48/00 ,  C12N15/60 ,  C12N15/12 ,  C12N7/01 ,  C12N5/10 ,  A61K39/235 ,  C12N9/88

CPC分类号： A61K48/005 ,  A61K38/00 ,  A61K48/00 ,  C12N9/88 ,  C12N2799/022 ,  C12N2799/025 ,  C12N2799/027 ,  C12N2799/028

公开(公告)号：EP1187919B1

公开(公告)日：2007-11-21

申请号：EP00940476.5

申请日：2000-06-08

申请人： Aventis Pharma S.A.

发明人： PERRICAUDET, Michel ,  SCHLUMBERGER, Martin ,  YEH, Patrice ,  BOLAND-AUGE, Anne

IPC分类号： C12N15/12 ,  C12N15/86 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K38/177 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2800/108

摘要： The invention concerns the field of gene therapy and the treatment of tumours. More particularly, the invention concerns the insertion of a gene coding for the iodine specific carrier (Na+/I- symporter) (NIS) in tumour cells using an adenoviral vector to promote the accumulation of iodine in said cells. The invention also concerns the defective recombinant adenoviruses for replication comprising the nis gene and the use of said vectors in a method for treating cancers combining nis gene transfer into tumour cells and metabolic radiotherapy.

公开(公告)号：EP0783585B1

公开(公告)日：2006-06-28

申请号：EP95932050.8

申请日：1995-09-22

申请人： Aventis Pharma S.A.

发明人： ORSINI, Cécile ,  PERRICAUDET, Michel ,  VIGNE, Emmanuelle ,  YEH, Patrice

IPC分类号： C12N15/86 ,  C07K14/075

CPC分类号： C12N15/86 ,  A61K48/00 ,  C07K14/005 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10362 ,  C12N2800/108

摘要： The present invention relates to new viral vectors derived from adenoviruses, their preparation and utilization in gene therapy. It relates particularly to deffective recombinant adenoviruses wherein the IVa2 gene at least is inactivated.

公开(公告)号：EP0719332B1

公开(公告)日：2004-07-28

申请号：EP94925523.6

申请日：1994-08-22

申请人： Aventis Pharma S.A. ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

发明人： HADDADA, Hedi ,  LOPEZ, Manuel ,  PERRICAUDET, Michel

IPC分类号： C12N15/23 ,  C12N15/28 ,  C12N5/10 ,  A61K48/00 ,  C07K14/525 ,  C07K14/57

CPC分类号： C07K14/57 ,  A61K38/00 ,  A61K48/00 ,  C07K14/525

摘要： Cell compositions containing mononuclear phagocyte systems cells, and their use in cell therapy, e.g. adoptive immunotherapy, are disclosed.

公开(公告)号：EP0809516B1

公开(公告)日：2001-08-22

申请号：EP96903080.8

申请日：1996-02-12

申请人： Aventis Pharma S.A. ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

发明人： BACH, Jean-François ,  CHATENOUD, Lucienne ,  HADDADA, Hedi ,  LEE, Martin ,  PERRICAUDET, Michel ,  WEBB, Michelle

IPC分类号： A61K48/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N2710/10343

摘要： A medicinal combination of at least one immunosuppressive agent and at least one recombinant adenovirus with a genome that includes a first recombinant DNA containing a therapeutic gene, and a second recombinant DNA containing an immunoprotective gene, for consecutive, intermittent and/or simultaneous use in in vivo and/or ex vivo exogenic transfections.

公开(公告)号：EP1108047A1

公开(公告)日：2001-06-20

申请号：EP99940416.3

申请日：1999-08-27

申请人： Aventis Pharma S.A.

发明人： VIGNE, Emmanuelle ,  DEDIEU, Jean-François ,  LATTA, Martine ,  YEH, Patrice ,  PERRICAUDET, Michel

IPC分类号： C12N15/86 ,  C12N15/34 ,  C12N15/43 ,  C12N15/58 ,  C12N7/01 ,  C12N9/72 ,  C07K14/075 ,  C07K14/105 ,  C07K14/78 ,  C07K14/50 ,  A61K48/00

CPC分类号： C07K14/005 ,  A61K48/00 ,  C07K14/501 ,  C07K14/78 ,  C07K2319/00 ,  C12N9/6462 ,  C12N15/86 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2770/32622 ,  C12N2770/32634 ,  C12N2810/40 ,  C12N2810/55 ,  C12N2810/60 ,  C12N2810/6018 ,  C12N2810/80 ,  C12N2810/851 ,  C12N2810/855 ,  C12N2810/857 ,  C12Y304/21073

摘要： Modification of internal sites of the adenovirus fiber protein and hexon protein permit effective targeting of adenovirus vectors. Accessible sites to redirect adenovirus targeting were identified. The HVR5 loop of the hexon protein and the HI loop of the fiber protein (knob) were highly permissive for the insertion of foreign protein sequences, which apparently did not impact on the viability and productivity of corresponding viruses. Accessibility and functionality of the epitope strongly depend on the size of the neighboring spacers. Other results suggest that short targeting peptides can be effectively fused to the C-terminus of the fiber protein. In a specific embodiment, a series of adenovirus vectors modified at the HVR5 site, the fiber protein HI loop, or the fiber protein C-terminus to target urokinase-type plasminogen activator receptor bearing cells were prepared. Such vectors are particularly useful for targeting the vasculature, e.g., for gene therapy of cancers or cardiovascular conditions.

公开(公告)号：EP0763116B2

公开(公告)日：2008-04-23

申请号：EP95920972.7

申请日：1995-05-22

申请人： Aventis Pharma S.A. ,  THE UNIVERSITY OF BRITISH COLUMBIA

发明人： BENOIT, Patrick ,  DENEFLE, Patrice ,  PERRICAUDET, Michel ,  HAYDEN, Michael R. ,  LEWIS, Marion Elizabeth Suzanne

IPC分类号： C12N15/55 ,  A61K38/43 ,  C12N15/86 ,  C12N5/10 ,  A61K48/00 ,  A61K9/22 ,  C12N7/01 ,  C12R1/91

CPC分类号： A61K48/005 ,  A61K38/00 ,  A61K38/465 ,  A61K48/00 ,  A61K2039/51 ,  C12N9/20 ,  C12N15/86 ,  C12N2710/10343 ,  C12Y301/01034

摘要： Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.